Naloxone for Opioid Overdose: Injection, 4 mg Nasal Spray, Dosing and Re-sedation Safety

Clinical review: 27 October 2026. Naloxone is a competitive opioid-receptor antagonist used to reverse opioid-induced respiratory depression. In a suspected overdose, airway support, emergency help and assisted ventilation are immediate priorities; do not wait for naloxone before supporting breathing. Naloxone’s effect may be shorter than the causative opioid, so recurrent sedation is possible.

When to suspect opioid toxicity

Markedly reduced consciousness with slow or inadequate breathing, especially after exposure to morphine, heroin, fentanyl, methadone or other opioids, warrants urgent assessment. Pinpoint pupils may occur but are not required. Check airway, breathing, circulation, glucose and alternative causes. If breathing is inadequate, give oxygen and bag-mask ventilation as indicated, summon emergency assistance and administer naloxone promptly.

Routes, strengths and labelled doses

Presentation or situation	Reference dosing information	Critical caution
Injectable naloxone, adult opioid overdose	US product labels describe an initial 0.4–2 mg IV, with additional doses every 2–3 minutes as needed for adequate respiratory response.	Titrate to effective ventilation rather than complete wakefulness. Lower incremental titration may be appropriate in opioid-dependent patients under a clinician’s protocol.
Injectable naloxone, paediatric overdose	Selected US labels describe 0.01 mg/kg IV initially; if insufficient, a subsequent 0.1 mg/kg may be used.	Use a paediatric emergency protocol, check the formulation and seek specialist advice. Neonatal resuscitation has separate guidance.
IV access unavailable	IM or SC injectable routes are options where labelled and feasible.	Onset may be slower; ventilation must continue.
Single-use 4 mg intranasal device	Give one device intranasally and use a new device for another dose if needed after 2–3 minutes, according to that product’s instructions.	4 mg intranasal is not pharmacokinetically equivalent to 4 mg IV. Verify the exact device and local availability.

Drug preparation and medication-error prevention

Injection strengths vary: some products contain 0.4 mg/mL, while other labelled presentations contain 1 mg/mL. Therefore, never assume a given milligram dose corresponds to a fixed millilitre volume. Read the ampoule or prefilled-syringe label, calculate from the actual concentration and double-check the route. A 4 mg nasal spray is a complete single-use device; it is not an injectable preparation.

For recurrent respiratory depression after repeated boluses, a monitored IV infusion may be necessary. Infusion concentration, diluent, stability and rate must follow the specific product’s prescribing information and institutional toxicology/critical-care protocol. A universal infusion rate cannot be safely inferred from a generic online example.

Monitoring and important adverse effects

Continuously reassess respiratory effort, respiratory rate, oxygenation, consciousness and the need for assisted ventilation.
Monitor for re-sedation, particularly after long-acting opioids or potent synthetic opioids. Observation and repeated treatment may be necessary.
Rapid reversal in opioid-dependent patients can precipitate withdrawal: agitation, nausea/vomiting, tachycardia, hypertension and aspiration risk.
Cardiopulmonary adverse events are reported; assess comorbidities and concurrent sedatives. Naloxone does not reverse non-opioid sedative toxicity.
Pregnancy, lactation, renal or hepatic dysfunction require clinical context, but lifesaving resuscitation should not be delayed.

Five common errors

Confusing mg and mL across vial strengths.
Delaying bag-mask ventilation while searching for naloxone.
Assuming an initial response means no further monitoring is needed.
Equating nasal and IV milligram doses.
Using high doses without reassessing alternative diagnoses or withdrawal risk.

Primary references

For trained clinicians; not a patient-specific prescription. US-labelled presentations do not establish India-market availability. Always verify the locally stocked Indian product, hospital protocol and emergency team instructions.